Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert J Ossenkoppele

Showing results (1-10 of 193) with videos related to

Pageof 20
Sort By:
Critical Reviews in Oncology/Hematology|June 2, 2019
Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal useValeria Santini, Gert J Ossenkoppele
Best Practice & Research. Clinical Haematology|December 3, 2014
MRD in AML: it is time to change the definition of remissionGert J Ossenkoppele, Gerrit Jan Schuurhuis
Hematology. American Society of Hematology. Education Program|December 7, 2019
Minimal residual disease and stem cell transplantation outcomesJacqueline Cloos, Gert J Ossenkoppele, Richard Dillon
Mediterranean Journal of Hematology and Infectious Diseases|March 19, 2013
Autologous Stem Cell Transplantation in elderly Acute Myeloid LeukemiaGert J Ossenkoppele, Jeroen Jwm Janssen, Peter C Huijgens
Blood Reviews|November 8, 2018
Prognostic and therapeutic role of CLEC12A in acute myeloid leukemiaLinde M Morsink, Roland B Walter, Gert J Ossenkoppele
Advances in Therapy|November 17, 2021
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid LeukemiaValeria Santini, Michael Lübbert, Agnieszka Wierzbowska, et al.
Expert Review of Hematology|November 24, 2018
Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardizationGerrit J Schuurhuis, Gert J Ossenkoppele, Angèle Kelder, et al.
Anti-Cancer Drugs|March 12, 2004
Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implicationsArjan A van de Loosdrecht, Peter C Huijgens, Gert J Ossenkoppele
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 21, 2007
Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemiaTheresia M Westers, Gert J Ossenkoppele, Arjan A van de Loosdrecht
British Journal of Haematology|March 10, 2011
Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasmsGert J Ossenkoppele, Arjan A van de Loosdrecht, Gerrit Jan Schuurhuis
Pageof 20

Showing results (1-10 of 193) with videos related to

Sort By:
Pageof 20
Critical Reviews in Oncology/Hematology|June 2, 2019
Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal useValeria Santini, Gert J Ossenkoppele
Best Practice & Research. Clinical Haematology|December 3, 2014
MRD in AML: it is time to change the definition of remissionGert J Ossenkoppele, Gerrit Jan Schuurhuis
Hematology. American Society of Hematology. Education Program|December 7, 2019
Minimal residual disease and stem cell transplantation outcomesJacqueline Cloos, Gert J Ossenkoppele, Richard Dillon
Mediterranean Journal of Hematology and Infectious Diseases|March 19, 2013
Autologous Stem Cell Transplantation in elderly Acute Myeloid LeukemiaGert J Ossenkoppele, Jeroen Jwm Janssen, Peter C Huijgens
Blood Reviews|November 8, 2018
Prognostic and therapeutic role of CLEC12A in acute myeloid leukemiaLinde M Morsink, Roland B Walter, Gert J Ossenkoppele
Advances in Therapy|November 17, 2021
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid LeukemiaValeria Santini, Michael Lübbert, Agnieszka Wierzbowska, et al.
Expert Review of Hematology|November 24, 2018
Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardizationGerrit J Schuurhuis, Gert J Ossenkoppele, Angèle Kelder, et al.
Anti-Cancer Drugs|March 12, 2004
Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implicationsArjan A van de Loosdrecht, Peter C Huijgens, Gert J Ossenkoppele
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 21, 2007
Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemiaTheresia M Westers, Gert J Ossenkoppele, Arjan A van de Loosdrecht
British Journal of Haematology|March 10, 2011
Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasmsGert J Ossenkoppele, Arjan A van de Loosdrecht, Gerrit Jan Schuurhuis
Pageof 20